Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers

NCT07116876 · View on ClinicalTrials.gov ↗

Study Summary

This study will evaluate Matrion™ (LifeNet Health, Inc., Virginia Beach, VA), a placental membrane product, as a treatment for diabetic foot ulcers compared to conventional wound care. Matrion is derived from donated human birth tissue and includes both the amniotic and chorionic layers, along with the trophoblast layer. It is minimally processed using a proprietary decellularization method and terminally sterilized to ensure the membrane is acellular and sterile, making it suitable for surgical applications.

Interventions

  • OTHER Graft Application
  • OTHER Wound Dressing Material

Study Locations (18)

California

  • Bay Area Foot Care — Castro Valley
  • Limb Preservaion Platform, Inc. — Fresno
  • Center for Clinical Research, Inc — San Francisco
  • Bay Area Foot Care — San Francisco
  • ILD Research Center — Vista

Florida

  • Humanity Clinical Research, Corp — Aventura
  • South Florida Podiatry — Deerfield Beach
  • Dinamo Research & Diagnostic Center, LLC — Hialeah
  • Doctors Research Network, Inc. — Miami

Texas

  • Olympus Clinical Research — Katy
  • Element Research Group — San Antonio
  • Olympus-Alcanza — Sugar Land

Illinois

  • Independent Clinical Research — Decatur
  • Independent Clinical Research, LLC — Springfield

North Carolina

  • US Foot and Ankle Specialists — Raleigh
  • Foot and Ankle Institute of the Carolinas — Rocky Mount

Arizona

  • Compass Medical Research Center — Tucson

Virginia

  • Foot and Ankle Specialists of the Mid-Atlantic — Salem

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-06-26
Est. Completion 2026-06
Phase NA

Sponsor

LifeNet Health

5 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07116876

The ClinicalTrials.gov registry entry for NCT07116876 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LifeNet Health, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Diabetic Foot Ulcer (DFU) appearing as the primary indexed condition, and to 2 interventions — of which Graft Application is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07116876 reports 18 study locations spanning 7 distinct geographic areas — top geographies include California, Florida, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07116876 about?

NCT07116876 is a clinical study titled "Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers". This study will evaluate Matrion™ (LifeNet Health, Inc., Virginia Beach, VA), a placental membrane product, as a treatment for diabetic foot ulcers compared to conventional wound care. Matrion is derived from donated human birth tissue and includes both the amniotic and chorionic layers, along with ...

What is the current status of trial NCT07116876?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-06-26. Estimated completion is 2026-06.

What conditions does trial NCT07116876 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer (DFU), Lower Extremity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07116876?

The interventions under investigation include: Graft Application (OTHER), Wound Dressing Material (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07116876?

This trial is sponsored by LifeNet Health, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07116876 being conducted?

This trial has 18 study locations across Arizona, California, Florida, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial